KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Accumulated Expenses for 18 consecutive years, with $946.5 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 34.41% year-over-year to $946.5 million; the TTM value through Mar 2026 reached $946.5 million, up 34.41%, while the annual FY2025 figure was $1.1 billion, 36.1% up from the prior year.
  • Accumulated Expenses hit $946.5 million in Q1 2026 for Alnylam Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.2 billion in Q3 2025 and bottomed at $355.9 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $730.4 million, with a median of $713.0 million recorded in 2023.
  • Year-over-year, Accumulated Expenses surged 42.89% in 2023 and then rose 0.76% in 2025.
  • Alnylam Pharmaceuticals' Accumulated Expenses stood at $545.5 million in 2022, then skyrocketed by 30.72% to $713.0 million in 2023, then rose by 11.32% to $793.7 million in 2024, then surged by 36.1% to $1.1 billion in 2025, then dropped by 12.38% to $946.5 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $946.5 million, $1.1 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.